

Ming-Sound Tsao

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6779123/ming-sound-tsao-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

508
papers

46,830
citations

90
h-index

209
g-index

565
ext. papers

55,111
ext. citations

7.2
avg, IF

7.41
L-index

#	Paper	IF	Citations
508	Effects of Ethnicity on Outcomes of Patients With Mutation-Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection.. <i>JTO Clinical and Research Reports</i> , 2022 , 3, 100259	1.4	0
507	The 2021 World Health Organization Classification of Tumors of the Pleura: Advances since the 2015 Classification.. <i>Journal of Thoracic Oncology</i> , 2022 ,	8.9	8
506	Integrin $\alpha 11$ in tumor fibrosis: more than just another cancer-associated fibroblast biomarker?. <i>Journal of Cell Communication and Signaling</i> , 2022 , 1	5.2	1
505	Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes.. <i>Nature Communications</i> , 2022 , 13, 1811	17.4	2
504	Assessing therapy response in patient-derived xenografts. <i>Science Translational Medicine</i> , 2021 , 13, eabf4969	17.5	2
503	The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211056306	5.4	1
502	Lung cancer driven by BRAF mutation is targetable by EGFR kinase inhibitors. <i>Journal of Thoracic Oncology</i> , 2021 ,	8.9	2
501	Chemical Genetics Screen Identifies COPB2 Tool Compounds That Alters ER Stress Response and Induces RTK Dysregulation in Lung Cancer Cells. <i>Journal of Molecular Biology</i> , 2021 , 433, 167294	6.5	2
500	The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors. <i>Nature Communications</i> , 2021 , 12, 6274	17.4	5
499	Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy.. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100251	1.4	1
498	Early innate and adaptive immune perturbations determine long-term severity of chronic virus and Mycobacterium tuberculosis coinfection. <i>Immunity</i> , 2021 , 54, 526-541.e7	32.3	8
497	The concept of mesothelioma in situ, with consideration of its potential impact on cytology diagnosis. <i>Pathology</i> , 2021 , 53, 446-453	1.6	8
496	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 686-696	8.9	2
495	Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers. <i>Scientific Reports</i> , 2021 , 11, 10619	4.9	1
494	Immune Resistance Interrogation Study (IRIS): A prospective comprehensive multi-omic analysis in patients with intrinsic and acquired resistance to immunotherapy.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS2679-TPS2679	2.2	
493	The value of defining molecular resistance in patients with progressive EGFR and ALK-driven lung cancer in a public system.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3126-3126	2.2	
492	Comparison of Nuclear Grade, Necrosis, and Histologic Subtype Between Biopsy and Resection in Pleural Malignant Mesothelioma: An International Multi-Institutional Analysis. <i>American Journal of Clinical Pathology</i> , 2021 , 156, 989-999	1.9	5

491	Sequencing of systemic therapies in advanced NSCLC with MET exon 14 skipping mutation: A multicenter experience.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e21123-e21123	2.2	1
490	Elderly patients with unresectable stage 3 NSCLC treated with definitive chemoradiation with or without durvalumab: Safety and outcomes.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 8547-8547	2.2	1
489	Impact of KRAS mutational variant on response to immunotherapy in metastatic NSCLC.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e21127-e21127	2.2	0
488	Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy. <i>Lung Cancer</i> , 2021 , 156, 76-81	5.9	2
487	Integration of multiomic annotation data to prioritize and characterize inflammation and immune-related risk variants in squamous cell lung cancer. <i>Genetic Epidemiology</i> , 2021 , 45, 99-114	2.6	2
486	Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. <i>Current Oncology</i> , 2021 , 28, 523-548	2.8	11
485	Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 190-197	21.7	14
484	Prognostic and predictive effect of gene copy number and mutation status in early stage non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2021 , 10, 826-838	4.4	1
483	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 345-362	19.4	148
482	Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway. <i>Cell Reports</i> , 2021 , 34, 108707	10.6	7
481	Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors. <i>Clinical Lung Cancer</i> , 2021 , 22, 253-259	4.9	17
480	Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. <i>Cancer Cell</i> , 2021 , 39, 1115-1134.e12	24.3	19
479	Risk Perception Among a Lung Cancer Screening Population. <i>Chest</i> , 2021 , 160, 718-730	5.3	2
478	Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1798-1809	8.9	8
477	Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer-A Cost-Efficient Strategy in a Public Healthcare System. <i>Current Oncology</i> , 2021 , 28, 3268-3279	2.8	4
476	Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1490-1500	8.9	3
475	Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges. <i>Lung Cancer</i> , 2021 , 162, 42-53	5.9	3
474	The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2021 , 160, 136-151	5.9	10

473	Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts. <i>Translational Oncology</i> , 2021 , 14, 101179	4.9	1
472	Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer. <i>Lung Cancer</i> , 2021 , 160, 127-135	5.9	5
471	Stratification and management of patients ineligible for lung cancer screening. <i>Respiratory Medicine</i> , 2021 , 188, 106610	4.6	
470	Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma. <i>Pharmaceuticals</i> , 2020 , 13,	5.2	4
469	Multivalent assembly of KRAS with the RAS-binding and cysteine-rich domains of CRAF on the membrane. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 12101-12108	11.5	22
468	Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories.. <i>JCO Precision Oncology</i> , 2020 , 4, 520-533	3.6	4
467	Protein-altering germline mutations implicate novel genes related to lung cancer development. <i>Nature Communications</i> , 2020 , 11, 2220	17.4	6
466	BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer. <i>Lung Cancer</i> , 2020 , 146, 78-85	5.9	6
465	Minimalist approaches to cancer tissue-of-origin classification by DNA methylation. <i>Modern Pathology</i> , 2020 , 33, 1874-1888	9.8	8
464	The role of FOXOs and autophagy in cancer and metastasis-Implications in therapeutic development. <i>Medicinal Research Reviews</i> , 2020 , 40, 2089-2113	14.4	9
463	ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases. <i>Lung Cancer</i> , 2020 , 146, 350-354	5.9	5
462	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1409-1424	8.9	80
461	Recapitulating pancreatic tumor microenvironment through synergistic use of patient organoids and organ-on-a-chip vasculature. <i>Advanced Functional Materials</i> , 2020 , 30, 2000545	15.6	24
460	Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1037-1053	8.9	27
459	Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy. <i>Clinical Cancer Research</i> , 2020 , 26, 3431-3442	12.9	21
458	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1599-1610	8.9	52
457	Comprehensive assessment of PD-L1 immunohistochemistry on paired tissue and cytology specimens from non-small cell lung cancer. <i>Lung Cancer</i> , 2020 , 146, 276-284	5.9	5
456	A drug discovery platform to identify compounds that inhibit EGFR triple mutants. <i>Nature Chemical Biology</i> , 2020 , 16, 577-586	11.7	15

455	A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. <i>Lung Cancer</i> , 2020 , 143, 1-11	5.9	14
454	Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). <i>Clinical Cancer Research</i> , 2020 , 26, 2477-2486	12.9	4
453	Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib. <i>Clinical Lung Cancer</i> , 2020 , 21, e488-e492	4.9	2
452	Canadian Multicenter Project on Standardization of Programmed Death-Ligand 1 Immunohistochemistry 22C3 Laboratory-Developed Tests for Pembrolizumab Therapy in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1328-1337	8.9	11
451	CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9502-9502	2.2	17
450	Polarimetric second-harmonic generation microscopy of the hierarchical structure of collagen in stage I-III non-small cell lung carcinoma. <i>Biomedical Optics Express</i> , 2020 , 11, 1851-1863	3.5	11
449	Role of the total mutation burden (TMB) and tumor-infiltrating lymphocytes (TILs) on the development of second primary cancer after complete resection of non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e21092-e21092	2.2	
448	Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e21080-e21080	2.2	
447	TCR clonality and Treg frequency as predictors of outcome in stage III NSCLC treated with durvalumab.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3050-3050	2.2	0
446	A phase III randomized trial of pleurectomy/decortication plus chemotherapy with or without adjuvant hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for malignant pleural mesothelioma (MPM) (NRG LU-006).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS9079-TPS9079	2.2	
445	Rapid expansion of M-MDSCs and association with high levels of plasma TSLP and primary resistance to PD-1 inhibitors in metastatic NSCLC.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3084-3084	2.2	
444	Genomic analysis of driver-negative lung adenocarcinoma (LA) in lifetime never smokers.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3571-3571	2.2	
443	EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models. <i>Lung Cancer</i> , 2020 , 145, 144-151	5.9	2
442	Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel. <i>Modern Pathology</i> , 2020 , 33, 281-296	9.8	19
441	Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 1162-1174	12.9	58
440	EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 29-49	8.9	58
439	Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020 , 159, 2082-2091.e1	1.5	18
438	The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 344-359	8.9	27

437	Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study. <i>Clinical Trials</i> , 2020 , 17, 202-211	1
436	PD-L1 lineage-specific quantification in malignant pleural effusions of lung adenocarcinoma by flow cytometry. <i>Lung Cancer</i> , 2020 , 148, 55-61	5.9 1
435	Point-of-Care Spirometry Identifies High-Risk Individuals Excluded from Lung Cancer Screening. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 1473-1477	10.2 1
434	Implementation of PD-L1 22C3 IHC pharmDx™ in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt [®] Prefixation. <i>Acta Cytologica</i> , 2020 , 64, 577-587	3 5
433	Patient-derived cell line, xenograft and organoid models in lung cancer therapy. <i>Translational Lung Cancer Research</i> , 2020 , 9, 2214-2232	4.4 17
432	Chronic obstructive pulmonary disease prevalence and prediction in a high-risk lung cancer screening population. <i>BMC Pulmonary Medicine</i> , 2020 , 20, 300	3.5 1
431	Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance). <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1748-1757	8.9 5
430	Circulating miR-16-5p, miR-92a-3p, and miR-451a in Plasma from Lung Cancer Patients: Potential Application in Early Detection and a Regulatory Role in Tumorigenesis Pathways. <i>Cancers</i> , 2020 , 12,	6.6 17
429	Management of screen-detected lung nodules: A Canadian partnership against cancer guidance document. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020 , 4, 236-265	0.6 1
428	Towards personalized induction therapy for esophageal adenocarcinoma: organoids derived from endoscopic biopsy recapitulate the pre-treatment tumor. <i>Scientific Reports</i> , 2020 , 10, 14514	4.9 14
427	Cancer proteome and metabolite changes linked to SHMT2. <i>PLoS ONE</i> , 2020 , 15, e0237981	3.7 7
426	Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020 , 25, 64-77	5.7 22
425	Malignant mesothelioma in situ: morphologic features and clinical outcome. <i>Modern Pathology</i> , 2020 , 33, 297-302	9.8 41
424	"Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. <i>Modern Pathology</i> , 2020 , 33, 4-17	9.8 73
423	Rho guanine nucleotide exchange factor ARHGEF10 is a putative tumor suppressor in pancreatic ductal adenocarcinoma. <i>Oncogene</i> , 2020 , 39, 308-321	9.2 8
422	A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer. <i>Investigational New Drugs</i> , 2020 , 38, 1077-1084	4.3 9
421	Prediction of lung cancer risk at follow-up screening with low-dose CT: a training and validation study of a deep learning method. <i>The Lancet Digital Health</i> , 2019 , 1, e353-e362	14.4 40
420	PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC. <i>Scientific Reports</i> , 2019 , 9, 12437	4.9 11

419	Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohort. <i>BMJ Open</i> , 2019 , 9, e024719	3	17
418	Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15 2019 , 7, 17		16
417	Elevated Platelet Count Appears to Be Causally Associated with Increased Risk of Lung Cancer: A Mendelian Randomization Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019 , 28, 935-942	4	12
416	ONECUT2 is a driver of neuroendocrine prostate cancer. <i>Nature Communications</i> , 2019 , 10, 278	17.4	72
415	LOXL1 Is Regulated by Integrin $\alpha 1$ and Promotes Non-Small Cell Lung Cancer Tumorigenicity. <i>Cancers</i> , 2019 , 11,	6.6	23
414	Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts. <i>Cancer Research</i> , 2019 , 79, 4539-4550	4.5	18
413	Computer-assisted image analysis of the tumor microenvironment on an oral tongue squamous cell carcinoma tissue microarray. <i>Clinical and Translational Radiation Oncology</i> , 2019 , 17, 32-39	4.6	10
412	Pulmonary Adenocarcinoma Pathology and Molecular Testing 2019 , 13-33		1
411	Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 123	12.8	12
410	Characterization of Distinct Populations of Carcinoma-Associated Fibroblasts from Non-Small Cell Lung Carcinoma Reveals a Role for ST8SIA2 in Cancer Cell Invasion. <i>Neoplasia</i> , 2019 , 21, 482-493	6.4	16
409	A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy. <i>Lung Cancer</i> , 2019 , 130, 135-142	5.9	5
408	Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 377-407	8.9	114
407	CD45CD326 Cells are Predictive of Poor Prognosis in Non-Small Cell Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2019 , 25, 6756-6763	12.9	5
406	Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1704-1717	8.9	6
405	Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population-based reflex testing. <i>Cancer</i> , 2019 , 125, 4043-4051	6.4	9
404	Somatic Alteration Burden Involving Non-Cancer Genes Predicts Prognosis in Early-Stage Non-Small Cell Lung Cancer. <i>Cancers</i> , 2019 , 11,	6.6	2
403	Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019 , 28, 1228-1237	4	5
402	Outcomes of Long-term Interval Rescreening With Low-Dose Computed Tomography for Lung Cancer in Different Risk Cohorts. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1003-1011	8.9	5

401	Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the Oncomine Comprehensive Assay (OCA) v3: Integrating expanded genomic sequencing into the Canadian publicly funded health care model.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2620-2620	2.2	5
400	Quantifying EpCAM heterogeneity of circulating-tumor-cells (CTCs) from small cell lung cancer (SCLC) patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20091-e20091	2.2	2
399	Bone metastases as predictors of treatment response and rapidly progressive disease in NSCLC patients on PD-1/PD-L1 immune checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20667 ² -e20667 ¹		
398	Clinical, pathological and genetic predictors of patient-derived xenograft (PDX) engraftment in EGFR-mutated lung adenocarcinoma (LUAD).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3110-3110	2.2	
397	Myeloid immunosuppressive state as a predictor of rapidly progressive phenotype and poor survival in advanced non-small cell lung cancer (NSCLC) patients treated with PD-1/PD-L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20594-e20594	2.2	
396	Methylation profiling of EGFR mutant primary and metastatic lung cancer with brain metastasis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20574-e20574	2.2	
395	Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019 , 27, 699-714	1.9	23
394	Predicting Malignancy Risk of Screen-Detected Lung Nodules-Mean Diameter or Volume. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 203-211	8.9	24
393	Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 25-36	8.9	49
392	Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019 , 20, e338-e345	4.9	7
391	Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. <i>Nature Communications</i> , 2019 , 10, 224	17.4	43
390	Systematic analyses of regulatory variants in DNase I hypersensitive sites identified two novel lung cancer susceptibility loci. <i>Carcinogenesis</i> , 2019 , 40, 432-440	4.6	3
389	Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer. <i>PLoS Computational Biology</i> , 2019 , 15, e1006596	5	29
388	LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019 , 20, 66-73.e6	4.9	14
387	A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 231-239.e7	3.8	27
386	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 323-358	8.9	241
385	Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections. <i>Laboratory Investigation</i> , 2018 , 98, 403-413	5.9	6
384	Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC). <i>BMC Cancer</i> , 2018 , 18, 429	4.8	1

383	Multiplexed Real-Time NMR GTPase Assay for Simultaneous Monitoring of Multiple Guanine Nucleotide Exchange Factor Activities from Human Cancer Cells and Organoids. <i>Journal of the American Chemical Society</i> , 2018 , 140, 4473-4476	16.4	3
382	Genomic Testing in Lung Cancer: Past, Present, and Future. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 323-334	7.3	17
381	Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , 2018 , 142, 408-419	5	52
380	Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 73-79	3.8	16
379	Molecular Testing in Lung Cancer 2018 , 164-177.e5		
378	The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer. <i>Lung Cancer</i> , 2018 , 123, 22-29	5.9	13
377	PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1302-1311	8.9	381
376	Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19. <i>Cell</i> , 2018 , 174, 564-575.e18	56.2	154
375	Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in -Mutant Lung Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018 , 24, 5990-6000	12.9	10
374	Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PivOTAL observational study. <i>PLoS ONE</i> , 2018 , 13, e0202865	3.7	35
373	Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. <i>Nature Communications</i> , 2018 , 9, 3221	17.4	29
372	A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies (CCTG IND.229)[NCT02649686].. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1029-1029	2.2	13
371	Lung cancer in never smokers from the Princess Margaret Cancer Centre. <i>Oncotarget</i> , 2018 , 9, 22559-22570	5.0	14
370	Upfront next generation sequencing in NSCLC: A publicly funded perspective.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12062-12062	2.2	1
369	The effect of prior smoking history on the molecular profile of EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8533-8533	2.2	
368	Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2995-3006	2.2	120
367	Differentially expressed microRNAs in lung adenocarcinoma invert effects of copy number aberrations of prognostic genes. <i>Oncotarget</i> , 2018 , 9, 9137-9155	3.3	6
366	Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. <i>Nature Communications</i> , 2018 , 9, 3927	17.4	24

365	Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1655-1667	8.9	50
364	Refined RIP-seq protocol for epitranscriptome analysis with low input materials. <i>PLoS Biology</i> , 2018 , 16, e2006092	9.7	56
363	Omega-3 Fatty Acids Prevent Early Pancreatic Carcinogenesis via Repression of the AKT Pathway. <i>Nutrients</i> , 2018 , 10,	6.7	18
362	Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018 , 7, 416-427	4.4	6
361	ALK-Rearranged Non-Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism. <i>Clinical Lung Cancer</i> , 2017 , 18, 156-161	4.9	56
360	TRIM14 is a Putative Tumor Suppressor and Regulator of Innate Immune Response in Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2017 , 7, 39692	4.9	27
359	Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck. <i>Cancer Treatment Reviews</i> , 2017 , 54, 43-57	14.4	11
358	The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1210-1222	8.9	73
357	PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 208-222	8.9	812
356	Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature Genetics</i> , 2017 , 49, 1126-1132	36.3	246
355	Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer. <i>Radiotherapy and Oncology</i> , 2017 , 123, 195-202	5.3	32
354	The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 334-346	8.9	67
353	Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study. <i>Lancet Oncology, The</i> , 2017 , 18, 1523-1531	21.7	93
352	Pleiotropy of genetic variants on obesity and smoking phenotypes: Results from the Oncoarray Project of The International Lung Cancer Consortium. <i>PLoS ONE</i> , 2017 , 12, e0185660	3.7	7
351	Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3867-3876	2.2	263
350	Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2018-2027	2.2	61
349	Synergy of WEE1 and mTOR Inhibition in Mutant -Driven Lung Cancers. <i>Clinical Cancer Research</i> , 2017 , 23, 6993-7005	12.9	17
348	Role of the Extracellular Matrix in Tumor Stroma: Barrier or Support? 2017 , 77-112		

347	Modeling Drug Resistance in PDX Models. <i>Molecular and Translational Medicine</i> , 2017 , 115-126	0.4	
346	Role for High-Affinity IgE Receptor in Prognosis of Lung Adenocarcinoma Patients. <i>Cancer Immunology Research</i> , 2017 , 5, 821-829	12.5	8
345	Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth. <i>Molecular and Cellular Proteomics</i> , 2017 , 16, 1864-1888	7.6	20
344	A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib. <i>Journal of Thoracic Oncology</i> , 2017 , 12, e200-e202	8.9	22
343	Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2017 , 111, 23-29	5.9	105
342	Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors. <i>International Journal of Cancer</i> , 2017 , 140, 662-673	7.5	44
341	A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017 , 18, e41-e47	4.9	2
340	Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2017 , 23, 1060-1067	12.9	32
339	Senescent Carcinoma-Associated Fibroblasts Upregulate IL8 to Enhance Prometastatic Phenotypes. <i>Molecular Cancer Research</i> , 2017 , 15, 3-14	6.6	59
338	BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial. <i>Clinical Cancer Research</i> , 2017 , 23, 2460-2470	12.9	7
337	Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5522-5522	2.2	3
336	Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study. <i>PLoS ONE</i> , 2017 , 12, e0177875	3.7	56
335	Biomarker analysis of the phase 3 TORCH trial for first line erlotinib chemotherapy in advanced non-small cell lung cancer patients. <i>Oncotarget</i> , 2017 , 8, 57528-57536	3.3	7
334	A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. <i>Oncotarget</i> , 2017 , 8, 69651-69662	3.3	20
333	Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts. <i>Oncotarget</i> , 2017 , 8, 84659-84670	3.3	12
332	A preclinical trial to evaluate therapies for BRCA-associated pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 332-332	2.2	
331	Patients' willingness to pay for blood-based EGFR T790M testing: Results from a Canadian validation study of circulating DNA T790M testing.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e18329-e18329	2.2	2
330	Evaluation of stored liquid biopsies for molecular profiling in patients with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9024-9024	2.2	

329	Use of a marketing plan for recruitment to a lung cancer screening study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1548-1548	2.2	
328	Transbronchial Lung Cryobiopsy for Interstitial Lung Disease Diagnosis: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , 2016 , 140, 1281-1284	5	18
327	Response to Yamamoto et al. <i>Journal of Thoracic Oncology</i> , 2016 , 11, e129-30	8.9	
326	A proposal for cellularity assessment for EGFR mutational analysis with a correlation with DNA yield and evaluation of the number of sections obtained from cell blocks for immunohistochemistry in non-small cell lung carcinoma. <i>Journal of Clinical Pathology</i> , 2016 , 69, 607-11	3.9	14
325	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , 2016 , 8, 109	14.4	149
324	Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 850-61	8.9	57
323	Low Prevalence of High-Grade Lesions Detected With Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study. <i>Chest</i> , 2016 , 150, 1015-1022	5.3	29
322	Computer Vision Tool and Technician as First Reader of Lung Cancer Screening CT Scans. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 709-717	8.9	25
321	Scientific Advances in Lung Cancer 2015. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 613-638	8.9	164
320	Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1223-30	2.2	194
319	Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 900-9	8.9	20
318	Abstract PR03: Molecular profiling of advanced solid tumors at Princess Margaret Cancer Centre and patient outcomes with genotype-matched clinical trials 2016 ,		6
317	Prognostic and predictive effects of TP53 mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11585-11585	2.2	6
316	A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer. <i>Oncotarget</i> , 2016 , 7, 25632-9	3.3	6
315	Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302. <i>Oncotarget</i> , 2016 , 7, 33571-80	3.3	35
314	SOX2 and PI3K Cooperate to Induce and Stabilize a Squamous-Committed Stem Cell Injury State during Lung Squamous Cell Carcinoma Pathogenesis. <i>PLoS Biology</i> , 2016 , 14, e1002581	9.7	28
313	From Solo in the Silo to Strategic Training Programs. <i>CBE Life Sciences Education</i> , 2016 , 15, le1	3.4	1
312	Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 312-23	8.9	39

311	Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , 2016 , 140, 1267-1272	5	80
310	ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients. <i>Cancer Epidemiology</i> , 2016 , 41, 50-6	2.8	5
309	Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model. <i>Clinical Lung Cancer</i> , 2016 , 17, 375-383.e2	4.9	10
308	Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients. <i>Lung Cancer</i> , 2016 , 92, 53-61	5.9	46
307	Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , 2016 , 140, 341-4	5	98
306	Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 157, 109-16	4.4	25
305	Anti-PD-1-associated organizing pneumonia in a responding melanoma patient. <i>Annals of Oncology</i> , 2016 , 27, 1649-50	10.3	10
304	An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 2248-2252	8.9	2
303	A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. <i>Nature</i> , 2016 , 538, 378-382	50.4	304
302	Phase II study of PX-866 in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015 , 17, 1270-4	1	63
301	Optimization of miRNA-seq data preprocessing. <i>Briefings in Bioinformatics</i> , 2015 , 16, 950-63	13.4	74
300	Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2472-80	2.2	76
299	Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3439-46	2.2	160
298	CHCHD2 Is Coamplified with EGFR in NSCLC and Regulates Mitochondrial Function and Cell Migration. <i>Molecular Cancer Research</i> , 2015 , 13, 1119-29	6.6	30
297	NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015 , 21, 2499-505	12.9	35
296	Analytical Performance of a 15-Gene Prognostic Assay for Early-Stage Non-Small-Cell Lung Carcinoma Using RNA-Stabilized Tissue. <i>Journal of Molecular Diagnostics</i> , 2015 , 17, 438-45	5.1	9
295	Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. <i>Nature Medicine</i> , 2015 , 21, 1364-71	50.5	403
294	A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy. <i>Cancer Cell</i> , 2015 , 28, 623-637	24.3	51

293	Patient-derived tumor xenograft models established from samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. <i>Lung Cancer</i> , 2015 , 89, 110-4	5.9	12
292	Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 985-9	8.9	208
291	Integrating RAS status into prognostic signatures for adenocarcinomas of the lung. <i>Clinical Cancer Research</i> , 2015 , 21, 1477-86	12.9	11
290	Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1172-80	8.9	27
289	Tumor tissue characterization using polarization-sensitive second harmonic generation microscopy 2015 ,		3
288	Predictive versus prognostic value of lung adenocarcinoma classification. <i>Journal of Clinical Oncology</i> , 2015 , 33, 225-6	2.2	2
287	Plasma pro-surfactant protein B and lung function decline in smokers. <i>European Respiratory Journal</i> , 2015 , 45, 1037-45	13.6	21
286	Predictive value of coexisting KRAS and TP53 mutations on response to chemotherapy in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 11060-11060	2.2	2
285	NCIC CTG IND.206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2594-2594	2.2	4
284	Prognostic effect of single versus multiple somatic mutations in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 7521-7521	2.2	3
283	Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers. <i>PLoS ONE</i> , 2015 , 10, e0121872	3.7	17
282	Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy. <i>Journal of Thoracic Disease</i> , 2015 , 7, 1898-906	2.6	11
281	Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. <i>Translational Lung Cancer Research</i> , 2015 , 4, 67-81	4.4	186
280	Personalized treatment outcomes in never smokers with advanced non-small cell lung cancer (NSCLC) in the Princess Margaret Cancer Centre.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e19006-e19006	2.2	
279	EGFR mutations in NSCLC: Does ethnicity influence outcomes?. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17633-e17633	2.2	
278	A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium. <i>Clinical Lung Cancer</i> , 2014 , 15, 52-7	4.9	21
277	The mammalian-membrane two-hybrid assay (MaMTH) for probing membrane-protein interactions in human cells. <i>Nature Methods</i> , 2014 , 11, 585-92	21.6	105
276	Proteomic profiles of human lung adeno and squamous cell carcinoma using super-SILAC and label-free quantification approaches. <i>Proteomics</i> , 2014 , 14, 795-803	4.8	24

275	Robust global microRNA expression profiling using next-generation sequencing technologies. <i>Laboratory Investigation</i> , 2014 , 94, 350-8	5.9	98
274	Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. <i>Gynecologic Oncology</i> , 2014 , 135, 184-9	4.9	69
273	Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2014 , 15, 1379-88	21.7	103
272	HPV-associated lung cancers: an international pooled analysis. <i>Carcinogenesis</i> , 2014 , 35, 1267-75	4.6	49
271	Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1012-9	2.2	74
270	Epidermal growth factor receptor mutation-specific immunohistochemical antibodies in lung adenocarcinoma. <i>Histopathology</i> , 2014 , 64, 826-39	7.3	18
269	The RhoGEF GEF-H1 is required for oncogenic RAS signaling via KSR-1. <i>Cancer Cell</i> , 2014 , 25, 181-95	24.3	64
268	A genetic sequence variant (GSV) at susceptibility loci of 5p15.33 (TERT-CLPTM1L) is associated with survival outcome in locally advanced and metastatic non-small-cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2014 , 84, 289-94	5.9	11
267	Genes and pathology of non-small cell lung carcinoma. <i>Seminars in Oncology</i> , 2014 , 41, 28-39	5.5	50
266	Predictive Tumor Biomarkers for EGFR Inhibitors 2014 , 435-453		2
265	p120RasGAP is a mediator of rho pathway activation and tumorigenicity in the DLD1 colorectal cancer cell line. <i>PLoS ONE</i> , 2014 , 9, e86103	3.7	12
264	Characterization of collagen in non-small cell lung carcinoma with second harmonic polarization microscopy. <i>Biomedical Optics Express</i> , 2014 , 5, 3562-7	3.5	34
263	National Working Group Meeting on ALK diagnostics in lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014 , 10 Suppl 2, 11-7	1.9	9
262	Integrated omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact. <i>Nature Communications</i> , 2014 , 5, 5469	17.4	67
261	Preparing for tomorrow: molecular diagnostics and the changing nonsmall cell lung cancer landscape. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014 , 10 Suppl 2, 2-10	1.9	3
260	A feasibility study evaluating Surgery for Mesothelioma After Radiation Therapy: the "SMART" approach for resectable malignant pleural mesothelioma. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 397-402	8.9	104
259	PI3K/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 239-47	8.9	26
258	Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1255-63	8.9	61

257	Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1449-58	8.9	32
256	The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) response to the USPSTF recommendations. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 141-3	8.9	20
255	Forty years of the international association for study of lung cancer pathology committee. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1740-9	8.9	4
254	Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1354-62	8.9	31
253	Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 59-64	8.9	162
252	Sample features associated with success rates in population-based EGFR mutation testing. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 947-956	8.9	56
251	Reply to C.G. Azzoli et al and C. Chouaid et al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3578-9	2.2	1
250	Assessment of hypoxia in the stroma of patient-derived pancreatic tumor xenografts. <i>Cancers</i> , 2014 , 6, 459-71	6.6	49
249	Preoperative window-of-opportunity (WOO) study of dacomitinib (Dac) in patients (Pts) with resectable oral cavity squamous cell carcinoma (OCC): Generation of a gene expression signature (DGS) as a predictor of Dac activity.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6041-6041	2.2	4
248	A targeted intervention to improve awareness to molecular testing in NSCLC.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6547-6547	2.2	1
247	Lung cancer in never-smokers from the Princess Margaret Cancer Centre.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8099-8099	2.2	1
246	Molecular profiling of patients (pts) with advanced colorectal cancer (CRC): Princess Margaret Cancer Centre experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 459-459	2.2	1
245	SOX15 and other SOX family members are important mediators of tumorigenesis in multiple cancer types. <i>Oncoscience</i> , 2014 , 1, 326-35	0.8	36
244	Prognostic markers in lung cancer: is it ready for prime time?. <i>Translational Lung Cancer Research</i> , 2014 , 3, 149-58	4.4	32
243	Molecular profiling of patients (pts) with advanced colorectal cancer (CRC): Princess Margaret Cancer Center experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3572-3572	2.2	
242	Biomarker testing and time-to-treatment decision in patients with advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6595-6595	2.2	
241	Canadian ALK (CALK): A multicenter, prospective study of concurrent ALK immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in NSCLC.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8070-8070	2.2	
240	Molecular Testing in Pulmonary Tumors 2014 , 211-228		

239	Regulation of pancreatic cancer growth by superoxide. <i>Molecular Carcinogenesis</i> , 2013 , 52, 555-67	5	32
238	Probability of cancer in pulmonary nodules detected on first screening CT. <i>New England Journal of Medicine</i> , 2013 , 369, 910-9	59.2	688
237	NKG2D regulates production of soluble TRAIL by ex vivo expanded human γ T cells. <i>European Journal of Immunology</i> , 2013 , 43, 3175-82	6.1	34
236	Applications of array-CGH for lung cancer. <i>Methods in Molecular Biology</i> , 2013 , 973, 297-324	1.4	4
235	ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2013 , 368, 1101-10	59.2	284
234	Human papilloma virus genome is rare in North American non-small cell lung carcinoma patients. <i>Lung Cancer</i> , 2013 , 79, 215-20	5.9	26
233	Molecular prognostication of non-small cell lung cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2013 , 25, 4-7	1.7	2
232	Long-term outcome after en bloc resection of non-small-cell lung cancer invading the pulmonary sulcus and spine. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1538-44	8.9	25
231	Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment. <i>Laboratory Investigation</i> , 2013 , 93, 397-407	5.9	22
230	In compressed lung tissue microscopic sections of adenocarcinoma in situ may mimic papillary adenocarcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2013 , 137, 1792-7	5	12
229	Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3320-6	2.2	227
228	Alkaline phosphatase ALPPL-2 is a novel pancreatic carcinoma-associated protein. <i>Cancer Research</i> , 2013 , 73, 1934-45	10.1	56
227	Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2173-81	2.2	214
226	KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 530-42	8.9	84
225	Prognostic value of fibroblast growth factor receptor 1 gene locus amplification in resected lung squamous cell carcinoma. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1371-7	8.9	27
224	The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer. <i>PLoS ONE</i> , 2013 , 8, e71676	3.7	25
223	Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer. <i>PLoS ONE</i> , 2013 , 8, e71670	3.7	62
222	Abstract B282: The PLK-4 inhibitor CFI-400945 reduces tumor growth in patient-derived pancreatic xenografts. 2013 ,		2

221	Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 11002-11002	2.2	8
220	Plasma osteopontin and the prognosis of pleural mesothelioma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 11109-11109	2.2	1
219	Phase II study of PX-866 in recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2053-2053	2.2	3
218	Canadian ALK (CALK): A pan-Canadian multicenter study to optimize and standardize ALK immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for ALK gene rearrangements.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8096-8096	2.2	2
217	Loss of canonical Smad4 signaling promotes KRAS driven malignant transformation of human pancreatic duct epithelial cells and metastasis. <i>PLoS ONE</i> , 2013 , 8, e84366	3.7	25
216	Genomic Pathology of Lung Cancer 2013 , 1-46		1
215	Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for treatment of biliary cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 196-196	2.2	
214	Performance of a prognostic genomic signature for early-stage NSCLC in matched fresh frozen and RNA-stabilized tissue.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7532-7532	2.2	
213	Clinical impact of EGFR mutation fraction and tumor cellularity in EGFR mutation positive NSCLC.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e19077-e19077	2.2	
212	Surgery for early non-small cell lung cancer with preoperative erlotinib (SELECT): A correlative biomarker study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7516-7516	2.2	
211	ALK-immunohistochemistry (IHC) standardization with D5F3 antibody in non-small cell lung carcinoma (NSCLC): An international consensus study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e22042-e22042	2.2	2
210	Prognostic and predictive effects of a gene expression signature for NRF2 pathway activation in lung squamous cell carcinoma (SqCC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7517-7517	2.2	
209	Effect of BRM promoter variants on survival outcomes of stage III-IV non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 11057-11057	2.2	1
208	Benchmarking population-based EGFR mutation testing in nonsquamous non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e19032-e19032	2.2	
207	Economic analysis of TORCH: Erlotinib versus cisplatin and gemcitabine as first-line therapy for advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, e19031-e19031	2.2	
206	Willingness of patients to provide biologic samples for pharmacogenomic testing.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 6543-6543	2.2	1
205	Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1830-1844	8.9	17
204	Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma. <i>Modern Pathology</i> , 2012 , 25, 758-66	9.8	82

203	Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. <i>New England Journal of Medicine</i> , 2012 , 367, 1417-27	59.2	213
202	First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3002-11	2.2	193
201	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. <i>Nature</i> , 2012 , 491, 399-405	405.4	1427
200	Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer. <i>Lung Cancer</i> , 2012 , 76, 235-41	5.9	25
199	Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype. <i>Lung Cancer</i> , 2012 , 77, 501-6	5.9	34
198	Comprehensive genomic characterization of squamous cell lung cancers. <i>Nature</i> , 2012 , 489, 519-25	50.4	2820
197	Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies. <i>Genome Medicine</i> , 2012 , 4, 84	14.4	14
196	Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. <i>PLoS ONE</i> , 2012 , 7, e37775	3.7	50
195	Lipocalin2 promotes invasion, tumorigenicity and gemcitabine resistance in pancreatic ductal adenocarcinoma. <i>PLoS ONE</i> , 2012 , 7, e46677	3.7	50
194	Ancillary testing in lung cancer diagnosis. <i>Pulmonary Medicine</i> , 2012 , 2012, 249082	5.3	13
193	L1 cell adhesion molecule promotes tumorigenicity and metastatic potential in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 1914-24	12.9	42
192	Expression of kallikrein-related peptidase 7 predicts poor prognosis in patients with unresectable pancreatic ductal adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1135-42	4	24
191	Association of the 15q25 and 5p15 lung cancer susceptibility regions with gene expression in lung tumor tissue. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1097-104	4	15
190	A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 963-72	8.9	25
189	Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1653-60	8.9	89
188	Characterization of lymphomas developing in immunodeficient mice implanted with primary human non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1101-8	8.9	34
187	Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1513-21	8.9	41
186	A phase II study of foretinib in triple-negative, recurrent/metastatic breast cancer: NCIC CTG trial IND.197 (NCT01147484).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1036-1036	2.2	3

185	Prognostic and predictive effects of KRAS mutation subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7007-7007	2.2	5
184	Abstract A29: Genomic alteration of E2F/Rb activates EZH2 in small cell lung cancer. <i>Clinical Cancer Research</i> , 2012 , 18, A29-A29	12.9	
183	Single nucleotide polymorphisms (SNPs) of the platinum pharmacogenetic and VEGF pathways: Association with survival of platinum-treated stage IV non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7586-7586	2.2	
182	The effect of two BRM promoter variants on the risk of stage I/II upper aerodigestive tract cancers.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10522-10522	2.2	3
181	Genetic sequence variant (GSV) in TERT-CLPTM1L (5p15.33 locus) and survival in platinum-treated stage-IV non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1535-1535	2.2	
180	Phase II study of PX-866 in recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2051-2051	2.2	
179	Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. <i>Cancer Discovery</i> , 2011 , 1, 78-89	24.4	389
178	Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1663-9	8.9	35
177	Genetic disruption of KEAP1/CUL3 E3 ubiquitin ligase complex components is a key mechanism of NF-kappaB pathway activation in lung cancer. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1521-9	8.9	47
176	A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1379-91	8.9	79
175	Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 139-47	8.9	53
174	EGFR mutations and lung cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2011 , 6, 49-69	34	387
173	Modified gateway system for double shRNA expression and Cre/lox based gene expression. <i>BMC Biotechnology</i> , 2011 , 11, 24	3.5	8
172	The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Head & Neck Oncology</i> , 2011 , 3, 11		68
171	Differential utilization of NF-kappaB RELA and RELB in response to extracellular versus intracellular polyIC stimulation in HT1080 cells. <i>BMC Immunology</i> , 2011 , 12, 15	3.7	7
170	Primary tumor xenografts of human lung adeno and squamous cell carcinoma express distinct proteomic signatures. <i>Journal of Proteome Research</i> , 2011 , 10, 161-74	5.6	23
169	Quantitative phospho-proteomic profiling of hepatocyte growth factor (HGF)-MET signaling in colorectal cancer. <i>Journal of Proteome Research</i> , 2011 , 10, 3200-11	5.6	22
168	Genomic and Cellular Pathology of Lung Cancer. <i>Current Respiratory Medicine Reviews</i> , 2011 , 7, 313-322	0.3	1

167	Optimized application of penalized regression methods to diverse genomic data. <i>Bioinformatics</i> , 2011 , 27, 3399-406	7.2	56
166	Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 7160-5	11.5	268
165	Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer. <i>Molecular and Cellular Biology</i> , 2011 , 31, 138-50	4.8	115
164	Interaction between MYC and MCL1 in the genesis and outcome of non-small-cell lung cancer. <i>Cancer Research</i> , 2011 , 71, 2212-21	10.1	37
163	The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 134-41	12.9	131
162	International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 244-85	8.9	3178
161	Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3278-85	2.2	274
160	Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. <i>PLoS Pathogens</i> , 2011 , 7, e1002240	7.6	345
159	TRAF6 is an amplified oncogene bridging the RAS and NF- κ B pathways in human lung cancer. <i>Journal of Clinical Investigation</i> , 2011 , 121, 4095-105	15.9	125
158	The landscape of somatic copy-number alteration across human cancers. <i>Nature</i> , 2010 , 463, 899-905	50.4	2590
157	International network of cancer genome projects. <i>Nature</i> , 2010 , 464, 993-8	50.4	1613
156	Transcriptome profiles of carcinoma-in-situ and invasive non-small cell lung cancer as revealed by SAGE. <i>PLoS ONE</i> , 2010 , 5, e9162	3.7	19
155	Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. <i>Journal of Clinical Oncology</i> , 2010 , 28, 29-34	2.2	279
154	Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21. <i>Journal of Clinical Oncology</i> , 2010 , 28, 5247-56	2.2	46
153	Re: Gene expression-based prognostic signatures in lung cancer: ready for clinical use?. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 1677-8; author reply 1678-9	9.7	7
152	Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4417-24	2.2	350
151	Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma. <i>PLoS Medicine</i> , 2010 , 7, e1000315	11.6	75
150	Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3316-22	2.2	84

149	FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. <i>Journal of Clinical Pathology</i> , 2010 , 63, 630-4	3.9	69
148	Prognostic gene expression signature for squamous cell carcinoma of lung. <i>Clinical Cancer Research</i> , 2010 , 16, 5038-47	12.9	26
147	Lung cancer screening using low-dose computed tomography in at-risk individuals: the Toronto experience. <i>Lung Cancer</i> , 2010 , 67, 177-83	5.9	82
146	Differential roles of cyclin D1 and D3 in pancreatic ductal adenocarcinoma. <i>Molecular Cancer</i> , 2010 , 9, 24	42.1	29
145	Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach. <i>Cancer Letters</i> , 2010 , 297, 126-36	9.9	44
144	Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 298-306	9.7	58
143	A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010 , 33, 609-13	2.7	56
142	Fibroblast growth factor inhibitors. <i>Journal of Thoracic Oncology</i> , 2010 , 5, S457	8.9	
141	Lung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors. <i>BMC Cancer</i> , 2010 , 10, 285	4.8	49
140	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. <i>Cancer</i> , 2010 , 116, 5599-607	6.4	127
139	Detection of EGFR and KRAS mutations in fine-needle aspirates stored on Whatman FTA cards: is this the tool for biobanking cytological samples in the molecular era?. <i>Cancer Cytopathology</i> , 2010 , 118, 450-6	3.9	42
138	A sequence-based approach to identify reference genes for gene expression analysis. <i>BMC Medical Genomics</i> , 2010 , 3, 32	3.7	36
137	HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. <i>Small</i> , 2010 , 6, 430-7	11	114
136	Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. <i>Journal of Clinical Investigation</i> , 2010 , 120, 3296-309	15.9	111
135	Prognostic gene signatures for non-small-cell lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 2824-8	11.5	159
134	Absence of caspase-3 protects pancreatic {beta}-cells from c-Myc-induced apoptosis without leading to tumor formation. <i>Journal of Biological Chemistry</i> , 2009 , 284, 10947-56	5.4	17
133	TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 797-802	11.5	103
132	Up-regulation of L1CAM in pancreatic duct cells is transforming growth factor beta1- and slug-dependent: role in malignant transformation of pancreatic cancer. <i>Cancer Research</i> , 2009 , 69, 4517-26	10.1	81

131	Induction chemoradiotherapy facilitates radical resection of T4 non-small cell lung cancer invading the spine. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2009 , 137, 441-447.e1	1.5	31
130	SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. <i>Nature Genetics</i> , 2009 , 41, 1238-42	36.3	733
129	Carcinoma-Associated Fibroblasts in Lung Cancer 2009 , 193-215		
128	A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. <i>American Journal of Human Genetics</i> , 2009 , 85, 679-91	11	442
127	Understanding prognostic gene expression signatures in lung cancer. <i>Clinical Lung Cancer</i> , 2009 , 10, 331-40	49	49
126	Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6229-36	2.2	77
125	Molecular predictive and prognostic markers in non-small-cell lung cancer. <i>Lancet Oncology</i> , 2009 , 10, 1001-10	21.7	167
124	Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. <i>Neoplasia</i> , 2009 , 11, 1292-300	6.4	55
123	Gene expression profiling of adenosine triphosphate-binding cassette transporters in response to K-ras activation and hypoxia in human pancreatic cancer cell cultures. <i>Pancreas</i> , 2009 , 38, 85-93	2.6	4
122	Defining genomic alteration boundaries for a combined small cell and non-small cell lung carcinoma. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 227-39	8.9	17
121	Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. <i>Modern Pathology</i> , 2008 , 21, 817-25	9.8	86
120	Frequent accumulation of nuclear E-cadherin and alterations in the Wnt signaling pathway in esophageal squamous cell carcinomas. <i>Modern Pathology</i> , 2008 , 21, 271-81	9.8	49
119	Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. <i>Nature Medicine</i> , 2008 , 14, 822-7	50.5	835
118	Neither ovariectomy nor progestin treatment prevents endometrial neoplasia in pten+/- mice. <i>Gynecologic Oncology</i> , 2008 , 108, 395-401	4.9	12
117	Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis. <i>BMC Cancer</i> , 2008 , 8, 43	4.8	48
116	Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008 , 135, 823-9	1.5	117
115	Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4268-75	2.2	600
114	TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. <i>Genes and Development</i> , 2008 , 22, 2677-91	12.6	330

113	Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 10155-60	11.5	59
112	Gab1 but not Grb2 mediates tumor progression in Met overexpressing colorectal cancer cells. <i>Carcinogenesis</i> , 2008 , 29, 647-55	4.6	44
111	Human pancreatic duct epithelial cell model for KRAS transformation. <i>Methods in Enzymology</i> , 2008 , 439, 1-13	1.7	28
110	Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 527-9	8.9	52
109	Further insight into the markers of methotrexate resistance in childhood acute lymphoblastic leukemia patients. <i>Personalized Medicine</i> , 2008 , 5, 325-329	2.2	
108	Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma--epigenetic downregulation of caspases. <i>International Journal of Cancer</i> , 2008 , 123, 1751-60	7.5	57
107	Quantitative image analysis of immunohistochemical stains using a CMYK color model. <i>Diagnostic Pathology</i> , 2007 , 2, 8	3	116
106	Cigarette smoke components inhibited intercellular communication and differentiation in human pancreatic ductal epithelial cells. <i>International Journal of Cancer</i> , 2007 , 120, 1855-62	7.5	26
105	Characterizing the cancer genome in lung adenocarcinoma. <i>Nature</i> , 2007 , 450, 893-8	50.4	900
104	UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium. <i>Gynecologic Oncology</i> , 2007 , 106, 305-10	4.9	58
103	Keratinocyte growth factor/fibroblast growth factor-7-regulated cell migration and invasion through activation of NF-kappaB transcription factors. <i>Journal of Biological Chemistry</i> , 2007 , 282, 6001-11	1.4	70
102	Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5240-7	2.2	244
101	Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3978-84	2.2	200
100	Abelson interactor protein-1 positively regulates breast cancer cell proliferation, migration, and invasion. <i>Molecular Cancer Research</i> , 2007 , 5, 1031-9	6.6	35
99	Integrin alpha 11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 11754-9	11.5	115
98	Three-gene prognostic classifier for early-stage non small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5562-9	2.2	195
97	Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. <i>Clinical Cancer Research</i> , 2007 , 13, 994-9	12.9	120
96	KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 3229-34	12.9	78

95	Should mutational analyses of tumor samples bypass histopathology?. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 375-6	8.9	5
94	Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models. <i>Pancreas</i> , 2007 , 35, e16-26	2.6	12
93	K-ras mutations in non-small-cell lung carcinoma: a review. <i>Clinical Lung Cancer</i> , 2006 , 8, 30-8	4.9	180
92	Large fragment Bst DNA polymerase for whole genome amplification of DNA from formalin-fixed paraffin-embedded tissues. <i>BMC Genomics</i> , 2006 , 7, 312	4.5	30
91	Grg1 acts as a lung-specific oncogene in a transgenic mouse model. <i>Cancer Research</i> , 2006 , 66, 1294-301	10.1	44
90	Genomic DNA functions as a universal external standard in quantitative real-time PCR. <i>Nucleic Acids Research</i> , 2006 , 34, e85	20.1	121
89	Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1219-20; author reply 1220-1	2.2	88
88	Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations. <i>Clinical Lung Cancer</i> , 2006 , 7 Suppl 4, S138-44	4.9	61
87	A review of erlotinib and its clinical use. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 177-93	4	53
86	C/EBP alpha mutations in lung cancer. <i>Lung Cancer</i> , 2006 , 53, 253-4	5.9	15
85	Expression of Wnt-signaling pathway proteins in intraductal papillary mucinous neoplasms of the pancreas: a tissue microarray analysis. <i>Human Pathology</i> , 2006 , 37, 212-7	3.7	43
84	Integrin-Linked Kinase Inhibitor KP-392 Demonstrates Clinical Benefits in an Orthotopic Human Non-small Cell Lung Cancer Model. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 771-779	8.9	17
83	Ethanol and the tobacco-specific carcinogen, NNK, contribute to signaling in immortalized human pancreatic duct epithelial cells. <i>Pancreas</i> , 2006 , 33, 53-62	2.6	24
82	Identification of novel lung genes in bronchial epithelium by serial analysis of gene expression. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2006 , 35, 651-61	5.7	48
81	Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria. <i>Journal of Thoracic Oncology</i> , 2006 , 1, S13-S19	8.9	100
80	KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. <i>Oncogene</i> , 2005 , 24, 4741-53	9.2	155
79	Erlotinib in lung cancer - molecular and clinical predictors of outcome. <i>New England Journal of Medicine</i> , 2005 , 353, 133-44	59.2	1594
78	Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3279-87	2.2	223

77	Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2005 , 352, 2589-97	59.2	1469
76	Chromosome 5p aberrations are early events in lung cancer: implication of glial cell line-derived neurotrophic factor in disease progression. <i>Oncogene</i> , 2005 , 24, 4806-12	9.2	55
75	DJ-1, a novel regulator of the tumor suppressor PTEN. <i>Cancer Cell</i> , 2005 , 7, 263-73	24.3	452
74	High-resolution chromosome arm 5p array CGH analysis of small cell lung carcinoma cell lines. <i>Genes Chromosomes and Cancer</i> , 2005 , 42, 308-13	5	39
73	Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer. <i>Molecular Carcinogenesis</i> , 2005 , 43, 215-24	5	68
72	The tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates proliferation of immortalized human pancreatic duct epithelia through beta-adrenergic transactivation of EGF receptors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005 , 131, 639-48	4.9	75
71	In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis. <i>Cancer Research</i> , 2005 , 65, 5045-53	10.1	102
70	A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 5526-33	12.9	85
69	The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 343-9	4	242
68	Epithelial-cadherin and beta-catenin expression changes in pancreatic intraepithelial neoplasia. <i>Clinical Cancer Research</i> , 2004 , 10, 1235-40	12.9	98
67	Overexpression of G1-S cyclins and cyclin-dependent kinases during multistage human pancreatic duct cell carcinogenesis. <i>Clinical Cancer Research</i> , 2004 , 10, 6598-605	12.9	34
66	Expression of chicken ovalbumin upstream promoter-transcription factor II enhances invasiveness of human lung carcinoma cells. <i>Cancer Research</i> , 2004 , 64, 5097-105	10.1	35
65	Skp2 gene copy number aberrations are common in non-small cell lung carcinoma, and its overexpression in tumors with ras mutation is a poor prognostic marker. <i>Clinical Cancer Research</i> , 2004 , 10, 1984-91	12.9	68
64	grb2 heterozygosity rescues embryonic lethality but not tumorigenesis in pten ^{+/-} mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 15358-63	11.5	15
63	Brca2 deficiency does not impair mammary epithelium development but promotes mammary adenocarcinoma formation in p53 ^(+/-) mutant mice. <i>Cancer Research</i> , 2004 , 64, 1959-65	10.1	37
62	Identification of 27 5' CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers. <i>Oncogene</i> , 2004 , 23, 8705-10	9.2	96
61	Modeling of lung cancer by an orthotopically growing H460SM variant cell line reveals novel candidate genes for systemic metastasis. <i>Oncogene</i> , 2004 , 23, 6316-24	9.2	29
60	Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray study. <i>Lung Cancer</i> , 2004 , 46, 197-204	5.9	39

59	Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 1725-30	11.5	139
58	Stability and heterogeneity of expression profiles in lung cancer specimens harvested following surgical resection. <i>Neoplasia</i> , 2004 , 6, 761-7	6.4	40
57	Dysregulated PTEN-PKB and negative receptor status in human breast cancer. <i>International Journal of Cancer</i> , 2003 , 104, 195-203	7.5	76
56	Genetic alterations of lung adenocarcinoma in relation to smoking and ethnicity. <i>Lung Cancer</i> , 2003 , 41, 91-9	5.9	18
55	The function of multiple I κ B : NF- κ B complexes in the resistance of cancer cells to Taxol-induced apoptosis. <i>Oncogene</i> , 2002 , 21, 6510-9	9.2	153
54	Novel candidate tumor marker genes for lung adenocarcinoma. <i>Oncogene</i> , 2002 , 21, 7598-604	9.2	78
53	High expression of Met/hepatocyte growth factor receptor suppresses tumorigenicity in NCI-H1264 lung carcinoma cells. <i>Experimental Cell Research</i> , 2002 , 273, 45-53	4.2	6
52	Peptide differential display of serum-free conditioned medium from cancer cell lines. <i>Cancer Letters</i> , 2002 , 176, 199-203	9.9	8
51	Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. <i>Cancer Research</i> , 2002 , 62, 3005-8	10.1	155
50	Loss of Brca2 and p53 synergistically promotes genomic instability and deregulation of T-cell apoptosis. <i>Cancer Research</i> , 2002 , 62, 6194-204	10.1	31
49	Primary Pulmonary Primitive Neuroectodermal Tumor (PNET). <i>Pathology Research and Practice</i> , 2001 , 197, 121-122	3.4	
48	Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. <i>Nature Genetics</i> , 2001 , 29, 396-403	36.3	400
47	Expression of active protein kinase B in T cells perturbs both T and B cell homeostasis and promotes inflammation. <i>Journal of Immunology</i> , 2001 , 167, 42-8	5.3	75
46	Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer. <i>Human Pathology</i> , 2001 , 32, 57-65	3.7	40
45	Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. <i>Journal of Pathology</i> , 2000 , 190, 150-6	9.4	91
44	Requirement for glycogen synthase kinase-3 β in cell survival and NF- κ B activation. <i>Nature</i> , 2000 , 406, 86-90	50.4	1210
43	Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. <i>American Journal of Pathology</i> , 2000 , 157, 1623-31	5.8	261
42	A study of smoking, p53 tumor suppressor gene alterations and non-small cell lung cancer. <i>Annals of Epidemiology</i> , 2000 , 10, 176-85	6.4	21

41	Co-expression of epidermal growth factor receptor and transforming growth factor-alpha is independent of ras mutations in lung adenocarcinoma. <i>Lung Cancer</i> , 2000 , 29, 151-7	5.9	47
40	Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line. <i>Neoplasia</i> , 2000 , 2, 226-34	6.4	45
39	Autotaxin expression in non-small-cell lung cancer. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1999 , 21, 216-22	5.7	101
38	Tight junction protein ZO-2 is differentially expressed in normal pancreatic ducts compared to human pancreatic adenocarcinoma. <i>International Journal of Cancer</i> , 1999 , 82, 137-44	7.5	50
37	zo-2 gene alternative promoters in normal and neoplastic human pancreatic duct cells. <i>International Journal of Cancer</i> , 1999 , 83, 349-58	7.5	27
36	zo-2 gene alternative promoters in normal and neoplastic human pancreatic duct cells 1999 , 83, 349		1
35	Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. <i>Lung Cancer</i> , 1998 , 20, 1-16	5.9	100
34	Comparative phenotypic studies of duct epithelial cell lines derived from normal human pancreas and pancreatic carcinoma. <i>American Journal of Pathology</i> , 1998 , 153, 263-9	5.8	124
33	ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. <i>International Journal of Cancer</i> , 1997 , 72, 739-45	7.5	61
32	Autocrine growth loop of the epidermal growth factor receptor in normal and immortalized human bronchial epithelial cells. <i>Experimental Cell Research</i> , 1996 , 223, 268-73	4.2	42
31	Malignant rhabdoid tumor of the colon. Report of a case with molecular analysis. <i>Diseases of the Colon and Rectum</i> , 1996 , 39, 1322-6	3.1	36
30	Characterization of human bronchial epithelial cells immortalized by the E6 and E7 genes of human papillomavirus type 16. <i>Experimental Cell Research</i> , 1994 , 212, 36-41	4.2	45
29	Enhanced expression of alpha-fetoprotein gene in cultured rat liver epithelial cells treated with N-methyl-N'-nitro-N-nitrosoguanidine. <i>Pathobiology</i> , 1993 , 61, 25-30	3.6	1
28	Annulate lamellae in a large cell lung carcinoma cell line with high expression of tyrosine kinase receptor and proto-oncogenes. <i>Ultrastructural Pathology</i> , 1992 , 16, 439-49	1.3	13
27	Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 1992 , 16, 259-68	6.7	130
26	p53 gene mutations in human endometrial carcinoma. <i>Molecular Carcinogenesis</i> , 1992 , 5, 250-3	5	69
25	Primary pulmonary adenocarcinoma with enteric differentiation. <i>Cancer</i> , 1991 , 68, 1754-7	6.4	59
24	Liposomal muramyl dipeptide therapy of experimental M5076 liver metastases in mice. <i>Cancer Immunology, Immunotherapy</i> , 1991 , 33, 85-90	7.4	13

23	Effect of proliferative state on glutathione S-transferase isoenzyme expression in cultured rat liver epithelial cells. <i>Carcinogenesis</i> , 1991 , 12, 2031-4	4.6	9
22	Expression of protein disulfide isomerase in cultured rat liver epithelial cells is unrelated to the growth inhibitory effect of TGF-beta 1. <i>Biochemical and Biophysical Research Communications</i> , 1991 , 174, 478-82	3.4	1
21	Regulation by epidermal growth factor of the expression of transforming growth factor-beta 1 mRNA in cultured rat liver epithelial cells. <i>Experimental Cell Research</i> , 1991 , 195, 214-7	4.2	7
20	Genotoxicity of pancreatic chemical carcinogens to propagable cultured normal pancreatic epithelial cells. <i>Experimental and Molecular Pathology</i> , 1990 , 53, 203-10	4.4	3
19	Sequential changes in epidermal growth factor receptor/ligand function in cultured rat liver epithelial cells transformed chemically in vitro. <i>Pathobiology</i> , 1990 , 58, 3-14	3.6	20
18	Hepatic sinusoidal fibrosis in agnogenic myeloid metaplasia. <i>American Journal of Clinical Pathology</i> , 1989 , 91, 302-5	1.9	14
17	Glutathione and glutathione S-transferases in clones of cultured rat liver epithelial cells that express varying activity of gamma-glutamyl transpeptidase. <i>Molecular Carcinogenesis</i> , 1989 , 2, 144-9	5	8
16	Activation of murine Kupffer cell tumoricidal activity by liposomes containing lipophilic muramyl dipeptide. <i>Hepatology</i> , 1988 , 8, 1046-50	11.2	36
15	Induction of gamma-glutamyl transpeptidase activity by all-trans retinoic acid in cultured rat liver epithelial cells. <i>Biochemical and Biophysical Research Communications</i> , 1988 , 157, 1039-45	3.4	6
14	Human papillomavirus-11 DNA in a patient with chronic laryngotracheobronchial papillomatosis and metastatic squamous-cell carcinoma of the lung. <i>New England Journal of Medicine</i> , 1987 , 317, 873-8	59.2	132
13	Inconsistent effects of all-trans retinoic acid on different clones of chemically transformed rat liver epithelial cells. <i>Carcinogenesis</i> , 1987 , 8, 497-501	4.6	5
12	Establishment of propagable epithelial cell lines from normal adult rat pancreas. <i>Experimental Cell Research</i> , 1987 , 168, 365-75	4.2	36
11	Regulation of growth of cultured hepatic epithelial cells by transferrin. <i>Experimental Cell Research</i> , 1987 , 171, 52-62	4.2	25
10	Inhibition of proliferation of cultured rat liver epithelial cells at specific cell cycle stages by transforming growth factor-beta. <i>Biochemical and Biophysical Research Communications</i> , 1987 , 143, 26-30	3.4	44
9	The effects of epidermal growth factor and the state of confluence on enzymatic activities of cultured rat liver epithelial cells. <i>Journal of Cellular Physiology</i> , 1986 , 126, 167-73	7	26
8	In vitro colonization ability appears soon after initiation of hepatocarcinogenesis in the rat. <i>Carcinogenesis</i> , 1986 , 7, 669-71	4.6	17
7	The modulation of growth of normal rat liver epithelial cells in calcium-poor medium by epidermal growth factor, phenobarbital, phorbol ester, and retinoic acid. <i>In Vitro</i> , 1985 , 21, 249-53		7
6	Biochemical effects of 12-O-tetradecanoylphorbol-13-acetate, retinoic acid, phenobarbital, and 5-azacytidine on a normal rat liver epithelial cell line. <i>Journal of Cellular Physiology</i> , 1984 , 121, 1-6	7	8

5	Cauda equina paraganglioma. <i>Canadian Journal of Neurological Sciences</i> , 1983 , 10, 266-9	1	8
4	Pathogenesis of pulmonary infarction. <i>American Journal of Medicine</i> , 1982 , 72, 599-606	2.4	64
3	Expression profiling by microarrays in colorectal cancer (Review). <i>Oncology Reports</i> ,	3.5	8
2	Whole Genomes Define Concordance of Matched Primary, Xenograft, and Organoid Models of Pancreas Cancer		2
1	Integrative Pharmacogenomics Analysis of Patient Derived Xenografts		1